首页 > 最新文献

Journal of the American College of Clinical Pharmacy : JACCP最新文献

英文 中文
National survey of transplant pharmacist ambulatory care practices 全国移植药剂师门诊护理实践调查
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-02 DOI: 10.1002/jac5.1949
Helen Sweiss Pharm.D., Lyndsey Bowman Anger Pharm.D., Ann Dao Kataria Pharm.D., Christina Doligalski Pharm.D., Aoife Iaria Pharm.D., Dana Pierce Pharm.D., Georgina Waldman Pharm.D., Alicia B. Lichvar Pharm.D.

Introduction

There has been sustained growth in transplant pharmacist positions. However, the scope of pharmacist involvement, frequency of patient visits with a transplant pharmacist, and description of the transplant pharmacists' role in the ongoing management of transplant recipients have not been well described.

Objective

To determine the prevalence and role of transplant pharmacists in the management of transplant recipients in the ambulatory care setting.

Methods

A 53-question online survey was developed with the primary outcome being the incidence of solid organ transplant (SOT) programs with ambulatory care pharmacy services. Secondary outcomes included describing the scope of ambulatory transplant pharmacist activities for posttransplant recipients. The survey was distributed via transplant listservs and remained open from April 25, 2023 to May 27, 2023.

Results

A total of 174 responses were included for analysis, with 47 (27%) being partial responses. The total number of pediatric adult and pediatric transplant centers in the United States was 248 with a total number of 748 active programs, giving an estimated response rate of 23.8%. Of those, 93.7% reported having ambulatory transplant pharmacy services. The median of ambulatory care full-time employees was 1 (interquartile range [IQR] 1–2) across the responding institutions. Transplant pharmacists were also involved in outpatient infusions (69.2%), immunization screening and administration (82.5%), telehealth services (57.0%), prescription refill authorization (61.0%) electronic medical record in-basket, or equivalent messaging tasks (91.1%).

Conclusion

The incidence of SOT pharmacist involvement in ambulatory care is overall high (93.7%). Analysis of this project allows for a better understanding of the landscape of SOT ambulatory care pharmacy services and can be used as an assessment for standard practice activities.

移植药剂师职位持续增长。然而,关于药剂师的参与范围、移植药剂师访问病人的频率以及移植药剂师在移植受者的持续管理中所扮演角色的描述还不够完善。
{"title":"National survey of transplant pharmacist ambulatory care practices","authors":"Helen Sweiss Pharm.D.,&nbsp;Lyndsey Bowman Anger Pharm.D.,&nbsp;Ann Dao Kataria Pharm.D.,&nbsp;Christina Doligalski Pharm.D.,&nbsp;Aoife Iaria Pharm.D.,&nbsp;Dana Pierce Pharm.D.,&nbsp;Georgina Waldman Pharm.D.,&nbsp;Alicia B. Lichvar Pharm.D.","doi":"10.1002/jac5.1949","DOIUrl":"10.1002/jac5.1949","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>There has been sustained growth in transplant pharmacist positions. However, the scope of pharmacist involvement, frequency of patient visits with a transplant pharmacist, and description of the transplant pharmacists' role in the ongoing management of transplant recipients have not been well described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the prevalence and role of transplant pharmacists in the management of transplant recipients in the ambulatory care setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 53-question online survey was developed with the primary outcome being the incidence of solid organ transplant (SOT) programs with ambulatory care pharmacy services. Secondary outcomes included describing the scope of ambulatory transplant pharmacist activities for posttransplant recipients. The survey was distributed via transplant listservs and remained open from April 25, 2023 to May 27, 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 174 responses were included for analysis, with 47 (27%) being partial responses. The total number of pediatric adult and pediatric transplant centers in the United States was 248 with a total number of 748 active programs, giving an estimated response rate of 23.8%. Of those, 93.7% reported having ambulatory transplant pharmacy services. The median of ambulatory care full-time employees was 1 (interquartile range [IQR] 1–2) across the responding institutions. Transplant pharmacists were also involved in outpatient infusions (69.2%), immunization screening and administration (82.5%), telehealth services (57.0%), prescription refill authorization (61.0%) electronic medical record in-basket, or equivalent messaging tasks (91.1%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The incidence of SOT pharmacist involvement in ambulatory care is overall high (93.7%). Analysis of this project allows for a better understanding of the landscape of SOT ambulatory care pharmacy services and can be used as an assessment for standard practice activities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 6","pages":"554-562"},"PeriodicalIF":0.0,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141402506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative study of journal article scholarly activity: Pharmacy practice dual-degree faculty versus single terminal-degree faculty members 期刊论文学术活动比较研究:药学实践双学位教师与单终生学位教师的比较研究
IF 1.3 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-27 DOI: 10.1002/jac5.1947
Rebecca Henkels Pharm.D., Casey Tak Ph.D., Kibum Kim Ph.D., Julia Zhu BS, Pharm.D., Darin Chao Pharm.D., Mark A. Munger Pharm.D., FCCP

Objective

The goals of the 2005 National Institutes of Health (NIH) Roadmap of the Future of Pharmacy Colleges emphasized the importance of bidirectional information flow in translational research to enhance drug discovery and research. Many dual-degree programs and pathways have been developed to meet this bidirectional information flow to enhance discovery and research, but limited data exists on the bibliometrics of these dual-degree Department of Pharmacy Practice faculties. To determine whether dual-degree programs enhance research, a four-outcome bibliometric analysis of United States Departments of Pharmacy Practice tenure-track (DPP-TT) dual-degree compared with DPP-TT single terminal-degree faculty was conducted over a 10-year period.

Methods

A search of PubMed of DPP-TT single and dual-degree faculty from January 10, 2010 to December 31, 2019 was performed. Faculty employed in DPP-TT were determined through published rosters in the American Association of Colleges of Pharmacy (AACP) rosters or college/school internet sites. Department of Pharmacy Practice faculty members' number of publications, number of citations per publication, h-index, and NIH iCite weighted Relative Citation Ratio (RCR) value were determined. Descriptive statistics and analysis of variance compared dual-degree with single terminal-degree DPP faculty data.

Results

Ninety-one institutions employed 348 DPP-TT dual-degree faculty that produced 7480 publications compared with 131 institutions with 1805 single terminal-degree faculty of 12 670 publications. Dual-degree DPP number of citations per publication (mean ± standard deviation [SD]) was 37.8 ± 86.8 with a journal impact factor (JIF) of 6.4 ± 14.3 compared to single-degree of 24.7 ± 90.8 (p < 0.001) with a JIF of 4.7 ± 80.8 (p < 0.001). Dual-degree faculty h-index was 14.7 ± 12.5 with a mean iCite weighted RCR of 54.8 ± 87.6 compared to single-degree faculty of 6.5 ± 8.9 (p < 0.001) with an RCR of 22.1 ± 65.3 (p < 0.001).

Conclusion

Department of Pharmacy Practice dual-degree faculty have significantly higher bibliometrics compared with single-degree DPP faculty.

2005 年美国国立卫生研究院(NIH)药学院未来路线图的目标强调了转化研究中双向信息流对促进药物发现和研究的重要性。许多双学位项目和途径都是为了满足这种双向信息流以促进发现和研究而开发的,但关于这些双学位药学实践系的文献计量学数据却很有限。为了确定双学位项目是否能提高研究水平,我们对美国药学实践系终身教职(DPP-TT)双学位教师与DPP-TT单终生学位教师进行了为期10年的四项成果文献计量分析。DPP-TT聘用的教师是通过美国药学院协会(AACP)名册或学院/学校互联网站公布的名册确定的。确定了药学实践系教师的论文数量、每篇论文的引用次数、h 指数和 NIH iCite 加权相对引用比 (RCR) 值。91所院校聘用了348名DPP-TT双学位教师,发表了7480篇论文;131所院校聘用了1805名单学位教师,发表了12670篇论文。双学位 DPP 每篇论文的引用次数(平均值 ± 标准差 [SD])为 37.8 ± 86.8,期刊影响因子 (JIF) 为 6.4 ± 14.3;而单学位 DPP 每篇论文的引用次数为 24.7 ± 90.8(P < 0.001),期刊影响因子 (JIF) 为 4.7 ± 80.8(P < 0.001)。双学位教师的 h 指数为 14.7 ± 12.5,iCite 加权 RCR 平均值为 54.8 ± 87.6,而单学位教师的 h 指数为 6.5 ± 8.9 (p < 0.001),RCR 平均值为 22.1 ± 65.3 (p < 0.001)。
{"title":"Comparative study of journal article scholarly activity: Pharmacy practice dual-degree faculty versus single terminal-degree faculty members","authors":"Rebecca Henkels Pharm.D.,&nbsp;Casey Tak Ph.D.,&nbsp;Kibum Kim Ph.D.,&nbsp;Julia Zhu BS, Pharm.D.,&nbsp;Darin Chao Pharm.D.,&nbsp;Mark A. Munger Pharm.D., FCCP","doi":"10.1002/jac5.1947","DOIUrl":"10.1002/jac5.1947","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The goals of the 2005 National Institutes of Health (NIH) Roadmap of the Future of Pharmacy Colleges emphasized the importance of bidirectional information flow in translational research to enhance drug discovery and research. Many dual-degree programs and pathways have been developed to meet this bidirectional information flow to enhance discovery and research, but limited data exists on the bibliometrics of these dual-degree Department of Pharmacy Practice faculties. To determine whether dual-degree programs enhance research, a four-outcome bibliometric analysis of United States Departments of Pharmacy Practice tenure-track (DPP-TT) dual-degree compared with DPP-TT single terminal-degree faculty was conducted over a 10-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A search of PubMed of DPP-TT single and dual-degree faculty from January 10, 2010 to December 31, 2019 was performed. Faculty employed in DPP-TT were determined through published rosters in the American Association of Colleges of Pharmacy (AACP) rosters or college/school internet sites. Department of Pharmacy Practice faculty members' number of publications, number of citations per publication, <i>h</i>-index, and NIH iCite weighted Relative Citation Ratio (RCR) value were determined. Descriptive statistics and analysis of variance compared dual-degree with single terminal-degree DPP faculty data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-one institutions employed 348 DPP-TT dual-degree faculty that produced 7480 publications compared with 131 institutions with 1805 single terminal-degree faculty of 12 670 publications. Dual-degree DPP number of citations per publication (mean ± standard deviation [SD]) was 37.8 ± 86.8 with a journal impact factor (JIF) of 6.4 ± 14.3 compared to single-degree of 24.7 ± 90.8 (<i>p</i> &lt; 0.001) with a JIF of 4.7 ± 80.8 (<i>p</i> &lt; 0.001). Dual-degree faculty <i>h</i>-index was 14.7 ± 12.5 with a mean iCite weighted RCR of 54.8 ± 87.6 compared to single-degree faculty of 6.5 ± 8.9 (<i>p</i> &lt; 0.001) with an RCR of 22.1 ± 65.3 (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Department of Pharmacy Practice dual-degree faculty have significantly higher bibliometrics compared with single-degree DPP faculty.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"631-636"},"PeriodicalIF":1.3,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140374192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a clinical pharmacist-led COVID-19 treatment consult service in two primary care seniors clinics 由临床药剂师主导的 COVID-19 治疗咨询服务对两家初级保健老年诊所的影响
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-25 DOI: 10.1002/jac5.1948
Caitlin Hart Pharm.D., Sunny A. Linnebur Pharm.D., FCCP, Danielle R. Fixen Pharm.D.

Introduction

Healthcare utilization due to COVID-19 infection is more prevalent in the older adult population. Nirmatrelvir/ritonavir is an oral antiviral option that can decrease the hospitalizations in older adults but has many of drug–drug interactions that need evaluation.

Objectives

The objective of this study was to evaluate the impact of a clinical pharmacist COVID-19 treatment consult service.

Methods

Clinical pharmacists were consulted to assess and provide COVID-19 therapy recommendations for adults 65 years and older who tested positive for COVID-19 in two primary care clinics. Recommendations for the most appropriate COVID-19 therapy were sent to the primary care provider for review and discussed with the patient. Healthcare utilization, reinfection with COVID-19, and safety of COVID-19 therapies were evaluated.

Results

One hundred and twenty four patients, average age of 82 years, received clinical pharmacy assessment for COVID-19 therapy. Pharmacists recommended treatment with nirmatrelvir/ritonavir in 80% of patients. Medication modifications due to drug–drug interactions were required in 88% of patients receiving nirmatrelvir/ritonavir. Thirteen patients were recommended or opted to receive alternative COVID-19 treatment while 36 patients declined COVID-19 treatment, despite provider and pharmacist recommendations. Nineteen patients had an emergency department visit or hospitalization related to COVID-19 within 30 days of pharmacy consult; 15 of the patients had been treated with COVID-19 therapy and 4 declined therapy (p = 0.58). Eight patients experienced reinfection with COVID-19. Only one patient reported an adverse event of hives within 30 days of receiving nirmatrelvir/ritonavir therapy.

Conclusion

A pharmacist-led consult service for evaluating and recommending COVID-19 antiviral therapies resulted in successful triage, while balancing management of drug interactions in a high-risk patient population. No significant difference was found in healthcare utilization or reinfection between patients who received a COVID-19 therapy and those who did not.

在老年人群中,因 COVID-19 感染而就医的情况更为普遍。本研究的目的是评估临床药剂师 COVID-19 治疗咨询服务的影响。在两家初级保健诊所,临床药剂师为 COVID-19 检测呈阳性的 65 岁及以上成年人提供咨询,以评估并提供 COVID-19 治疗建议。最合适的 COVID-19 治疗建议将发送给初级保健提供者进行审核,并与患者进行讨论。124名平均年龄为82岁的患者接受了COVID-19疗法的临床药学评估。药剂师建议80%的患者使用尼马瑞韦/利托那韦治疗。88%接受尼尔马特韦/利托那韦治疗的患者因药物间相互作用而需要调整用药。有 13 名患者被推荐或选择接受 COVID-19 的替代治疗,有 36 名患者不顾医护人员和药剂师的建议,拒绝接受 COVID-19 治疗。19名患者在药房咨询后30天内曾因COVID-19到急诊科就诊或住院;其中15名患者接受过COVID-19治疗,4名患者拒绝接受治疗(P = 0.58)。8名患者再次感染了COVID-19。由药剂师主导的评估和推荐 COVID-19 抗病毒疗法的咨询服务成功实现了分流,同时兼顾了对高危患者群体药物相互作用的管理。接受COVID-19疗法的患者与未接受该疗法的患者在使用医疗服务或再感染方面没有明显差异。
{"title":"Impact of a clinical pharmacist-led COVID-19 treatment consult service in two primary care seniors clinics","authors":"Caitlin Hart Pharm.D.,&nbsp;Sunny A. Linnebur Pharm.D., FCCP,&nbsp;Danielle R. Fixen Pharm.D.","doi":"10.1002/jac5.1948","DOIUrl":"10.1002/jac5.1948","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Healthcare utilization due to COVID-19 infection is more prevalent in the older adult population. Nirmatrelvir/ritonavir is an oral antiviral option that can decrease the hospitalizations in older adults but has many of drug–drug interactions that need evaluation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study was to evaluate the impact of a clinical pharmacist COVID-19 treatment consult service.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical pharmacists were consulted to assess and provide COVID-19 therapy recommendations for adults 65 years and older who tested positive for COVID-19 in two primary care clinics. Recommendations for the most appropriate COVID-19 therapy were sent to the primary care provider for review and discussed with the patient. Healthcare utilization, reinfection with COVID-19, and safety of COVID-19 therapies were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and twenty four patients, average age of 82 years, received clinical pharmacy assessment for COVID-19 therapy. Pharmacists recommended treatment with nirmatrelvir/ritonavir in 80% of patients. Medication modifications due to drug–drug interactions were required in 88% of patients receiving nirmatrelvir/ritonavir. Thirteen patients were recommended or opted to receive alternative COVID-19 treatment while 36 patients declined COVID-19 treatment, despite provider and pharmacist recommendations. Nineteen patients had an emergency department visit or hospitalization related to COVID-19 within 30 days of pharmacy consult; 15 of the patients had been treated with COVID-19 therapy and 4 declined therapy (<i>p</i> = 0.58). Eight patients experienced reinfection with COVID-19. Only one patient reported an adverse event of hives within 30 days of receiving nirmatrelvir/ritonavir therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A pharmacist-led consult service for evaluating and recommending COVID-19 antiviral therapies resulted in successful triage, while balancing management of drug interactions in a high-risk patient population. No significant difference was found in healthcare utilization or reinfection between patients who received a COVID-19 therapy and those who did not.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 6","pages":"529-534"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Professional and career development needs of clinical pharmacists in settings outside academia 学术界以外临床药剂师的专业和职业发展需求
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-24 DOI: 10.1002/jac5.1940
Sarah M. Hayes Pharm.D., Donald C. Moore Pharm.D., FCCP, Madeline Droney Pharm.D., Steven T. Johnson Pharm.D., Megan A. Rech Pharm.D., M.S., FCCP, Kelsey M. Rife Pharm.D., Rowan Rosewarne Pharm.D., MPH, Richard J. Silvia Pharm.D., M.A., FCCP, Thomas Szymanski Pharm.D.

Clinical pharmacists practicing in academia have access to resources and pathways for professional development that clinical pharmacists practicing outside of academia may lack. With timely concerns of premature attrition and burnout in the clinical pharmacy profession, it is critical that employers and professional organizations help meet the professional development needs of clinical pharmacists practicing in outside of academia. Implementation of career ladders, creation of hybrid leadership-practice positions, achievement of operational excellence, cultivation of a positive culture, and development of optimal metrics may all help employers meet these needs. Professional organizations are called on to provide clinical pharmacists with a clear path for advancement within the organization to contribute to their ongoing professional development; this centers on the development of mentorship programs and opportunities to expand the professional portfolio of the clinical pharmacist practicing outside of academia. It is imperative that employers and professional organizations address the lack of existing career advancement and professional development opportunities to combat the premature attrition of clinical pharmacists from practice, improve the “life span” of the clinical pharmacist, and ultimately maintain the clinical pharmacy profession as a whole.

在学术界执业的临床药师可以获得专业发展的资源和途径,而在学术界以外执业的临床药师可能缺乏这些资源和途径。随着人们对临床药学专业人员过早流失和职业倦怠的及时关注,雇主和专业组织帮助满足在学术界以外执业的临床药师的专业发展需求至关重要。实施职业阶梯、设立领导与实践混合职位、实现卓越运营、培养积极的企业文化以及制定最佳衡量标准,这些都可以帮助雇主满足这些需求。专业组织应为临床药师提供在组织内晋升的明确途径,以促进他们的持续专业发展;这主要体现在导师计划的发展和扩大临床药师在学术界以外执业的专业组合的机会上。当务之急是,雇主和专业组织应解决目前缺乏职业晋升和专业发展机会的问题,以解决临床药师过早流失的问题,延长临床药师的 "寿命",并最终维护整个临床药学专业。
{"title":"Professional and career development needs of clinical pharmacists in settings outside academia","authors":"Sarah M. Hayes Pharm.D.,&nbsp;Donald C. Moore Pharm.D., FCCP,&nbsp;Madeline Droney Pharm.D.,&nbsp;Steven T. Johnson Pharm.D.,&nbsp;Megan A. Rech Pharm.D., M.S., FCCP,&nbsp;Kelsey M. Rife Pharm.D.,&nbsp;Rowan Rosewarne Pharm.D., MPH,&nbsp;Richard J. Silvia Pharm.D., M.A., FCCP,&nbsp;Thomas Szymanski Pharm.D.","doi":"10.1002/jac5.1940","DOIUrl":"https://doi.org/10.1002/jac5.1940","url":null,"abstract":"<p>Clinical pharmacists practicing in academia have access to resources and pathways for professional development that clinical pharmacists practicing outside of academia may lack. With timely concerns of premature attrition and burnout in the clinical pharmacy profession, it is critical that employers and professional organizations help meet the professional development needs of clinical pharmacists practicing in outside of academia. Implementation of career ladders, creation of hybrid leadership-practice positions, achievement of operational excellence, cultivation of a positive culture, and development of optimal metrics may all help employers meet these needs. Professional organizations are called on to provide clinical pharmacists with a clear path for advancement within the organization to contribute to their ongoing professional development; this centers on the development of mentorship programs and opportunities to expand the professional portfolio of the clinical pharmacist practicing outside of academia. It is imperative that employers and professional organizations address the lack of existing career advancement and professional development opportunities to combat the premature attrition of clinical pharmacists from practice, improve the “life span” of the clinical pharmacist, and ultimately maintain the clinical pharmacy profession as a whole.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 4","pages":"402-407"},"PeriodicalIF":0.0,"publicationDate":"2024-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From education to practice—2024 update: An opinion paper of the Drug Information Practice and Research Network of the American College of Clinical Pharmacy 从教育到实践--2024 年更新:美国临床药学院药物信息实践与研究网络的意见书
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-21 DOI: 10.1002/jac5.1945
Steven Theodore Johnson Pharm.D., Micheline Andel Goldwire Pharm.D., M.S., M.A., Maha Abdalla Pharm.D., Ph.D., Wafa H. Al-Shehre Pharm.D., Allison Bernknopf Pharm.D., MSMI, Angela Colella Pharm.D., Christie Denton Pharm.D., Janine S. Douglas Pharm.D., Rena Gosser Pharm.D., Gregory Heindel Pharm.D., Megan Holsopple Pharm.D., Heather Ipema Pharm.D., Karen Kier Ph.D., M.Sc, FCCP, Audrey Kostrzewa Pharm.D., MPH, Dan Majerczyk Pharm.D., FCCP, Dianne May Pharm.D., FCCP, J. Russell May Pharm.D., Sarah Turley Mersek Pharm.D., Faria Munir Pharm.D., M.S., Maha Saad Pharm.D., Christine D. Sommer Pharm.D., M.A., Krisy-Ann Thornby Pharm.D., Kristina E. Ward Pharm.D.

Drug information specialists (DIS) bring unique, specialized expertise and provide services in diverse settings including health systems, academia, pharmaceutical industry, compendia, medical writing, and other areas. With widespread access to drug information (DI) resources through user-friendly, online platforms, the role of DIS has shifted. Core skill sets once confined to DIS are now distributed across various non-DIS clinical specialties. DIS have transformed the application of their specialized skill set and adapted it to a variety of traditional and nontraditional areas, providing and applying advanced expertise to solve a variety of contemporary challenges. The training of students and residents has evolved to include evidence-based practical contemporary methods that promote critical thinking and reasoning. Effective DI evaluation and communication necessitates customizing content for stakeholders to ensure understanding and contribute to optimal patient care, all while addressing misinformation and disinformation. The future of DI as a specialty is bright, with ever-increasing recognition of the importance of DI skills in non-DIS practitioners. DIS will likely continue to guide best practices in the education/training of new practitioners and continue to provide advanced services and formulary analytics. This update to our 2009 DI PRN Opinion paper will focus on: (1) DI education and training needed for all students, residents, and pharmacists; (2) career opportunities, roles, and responsibilities specifically tailored for DIS in health systems, managed care organizations, academia, pharmaceutical/biotechnology industry, and medical writing services; and (3) the future direction of DI, including the potential impact of artificial intelligence.

药物信息专家 (DIS) 具有独特的专业知识,可在卫生系统、学术界、制药业、简编、医学写作等不同领域提供服务。随着通过方便用户的在线平台广泛获取药物信息(DI)资源,药物信息专家的角色发生了转变。曾经仅限于 DIS 使用的核心技能组合现在分布在各种非 DIS 临床专业领域。DIS 改变了其专业技能组合的应用方式,将其应用于各种传统和非传统领域,提供并应用先进的专业知识来解决各种当代挑战。对学生和住院医师的培训已发展到包括以证据为基础的实用现代方法,以促进批判性思维和推理。有效的诊断评估和交流需要为利益相关者定制内容,以确保理解并促进最佳的患者护理,同时解决误导和虚假信息问题。DI 作为一门专业的前景是光明的,非 DI 从业人员越来越认识到 DI 技能的重要性。DI 将继续指导新从业人员教育/培训方面的最佳实践,并继续提供先进的服务和处方分析。本文件是对 2009 年 DI PRN 意见书的更新,将重点关注以下方面:(1) 所有学生、住院医师和药剂师所需的 DI 教育和培训;(2) 医疗系统、管理式医疗机构、学术界、制药/生物技术行业和医学写作服务中专门为 DIS 量身定制的职业机会、角色和职责;以及 (3) DI 的未来发展方向,包括人工智能的潜在影响。
{"title":"From education to practice—2024 update: An opinion paper of the Drug Information Practice and Research Network of the American College of Clinical Pharmacy","authors":"Steven Theodore Johnson Pharm.D.,&nbsp;Micheline Andel Goldwire Pharm.D., M.S., M.A.,&nbsp;Maha Abdalla Pharm.D., Ph.D.,&nbsp;Wafa H. Al-Shehre Pharm.D.,&nbsp;Allison Bernknopf Pharm.D., MSMI,&nbsp;Angela Colella Pharm.D.,&nbsp;Christie Denton Pharm.D.,&nbsp;Janine S. Douglas Pharm.D.,&nbsp;Rena Gosser Pharm.D.,&nbsp;Gregory Heindel Pharm.D.,&nbsp;Megan Holsopple Pharm.D.,&nbsp;Heather Ipema Pharm.D.,&nbsp;Karen Kier Ph.D., M.Sc, FCCP,&nbsp;Audrey Kostrzewa Pharm.D., MPH,&nbsp;Dan Majerczyk Pharm.D., FCCP,&nbsp;Dianne May Pharm.D., FCCP,&nbsp;J. Russell May Pharm.D.,&nbsp;Sarah Turley Mersek Pharm.D.,&nbsp;Faria Munir Pharm.D., M.S.,&nbsp;Maha Saad Pharm.D.,&nbsp;Christine D. Sommer Pharm.D., M.A.,&nbsp;Krisy-Ann Thornby Pharm.D.,&nbsp;Kristina E. Ward Pharm.D.","doi":"10.1002/jac5.1945","DOIUrl":"10.1002/jac5.1945","url":null,"abstract":"<p>Drug information specialists (DIS) bring unique, specialized expertise and provide services in diverse settings including health systems, academia, pharmaceutical industry, compendia, medical writing, and other areas. With widespread access to drug information (DI) resources through user-friendly, online platforms, the role of DIS has shifted. Core skill sets once confined to DIS are now distributed across various non-DIS clinical specialties. DIS have transformed the application of their specialized skill set and adapted it to a variety of traditional and nontraditional areas, providing and applying advanced expertise to solve a variety of contemporary challenges. The training of students and residents has evolved to include evidence-based practical contemporary methods that promote critical thinking and reasoning. Effective DI evaluation and communication necessitates customizing content for stakeholders to ensure understanding and contribute to optimal patient care, all while addressing misinformation and disinformation. The future of DI as a specialty is bright, with ever-increasing recognition of the importance of DI skills in non-DIS practitioners. DIS will likely continue to guide best practices in the education/training of new practitioners and continue to provide advanced services and formulary analytics. This update to our 2009 DI PRN Opinion paper will focus on: (1) DI education and training needed for all students, residents, and pharmacists; (2) career opportunities, roles, and responsibilities specifically tailored for DIS in health systems, managed care organizations, academia, pharmaceutical/biotechnology industry, and medical writing services; and (3) the future direction of DI, including the potential impact of artificial intelligence.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 5","pages":"492-504"},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140221851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating learners into research and quality improvement projects: A joint opinion of the Adult Medicine and Education and Training Practice Research Networks of the American College of Clinical Pharmacy 将学员纳入研究和质量改进项目:美国临床药学院成人医学和教育培训实践研究网络的联合意见
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-19 DOI: 10.1002/jac5.1944
Taylor D. Steuber Pharm.D., Jimmy Gonzalez Pharm.D., Alex N. Isaacs Pharm.D., M.S., Kristi W. Kelley Pharm.D., FCCP, Sarah A. Nisly Pharm.D., M.Ed., FCCP, Jennifer A. Szwak Pharm.D., FCCP, Lisa Hong Pharm.D., Meredith L. Howard Pharm.D.

Research plays a vital role in advancing the pharmacy profession and improving patient care. It is a fundamental skill for learners to develop during their training under guided mentorship. Incorporating learners into research and quality improvement (QI) projects can yield numerous benefits for the learner, mentor, and institution. Despite this, there are barriers to integrating learners into research and QI projects which may stem from institutions and individuals. To ensure success when engaging in the research process, strategies centered around clear communication and illustrating the value should be implemented. Successful research programs require planning strategically, setting clear expectations, providing mentorship, and remaining adaptable to overcome barriers encountered during the process. The purpose of this paper is to discuss barriers to incorporating learners into research and QI projects and provide both mentors and learners strategies, tips and examples for success with perspectives and opinions from the American College of Clinical Pharmacy Adult Medicine and Education and Training Practice Research Networks.

研究在推动药学专业发展和改善患者护理方面发挥着至关重要的作用。这是学员在导师指导下接受培训期间需要掌握的一项基本技能。让学员参与研究和质量改进 (QI) 项目可为学员、导师和机构带来诸多益处。尽管如此,让学员参与研究和质量改进(QI)项目可能会遇到来自机构和个人的障碍。为确保成功参与研究过程,应实施以清晰沟通和说明价值为中心的策略。成功的研究项目需要战略规划、设定明确的期望、提供指导,并保持适应性,以克服过程中遇到的障碍。本文旨在讨论将学习者纳入研究和质量改进项目的障碍,并通过美国临床药学成人医学学院和教育培训实践研究网络的观点和意见,为指导者和学习者提供成功的策略、技巧和范例。
{"title":"Integrating learners into research and quality improvement projects: A joint opinion of the Adult Medicine and Education and Training Practice Research Networks of the American College of Clinical Pharmacy","authors":"Taylor D. Steuber Pharm.D.,&nbsp;Jimmy Gonzalez Pharm.D.,&nbsp;Alex N. Isaacs Pharm.D., M.S.,&nbsp;Kristi W. Kelley Pharm.D., FCCP,&nbsp;Sarah A. Nisly Pharm.D., M.Ed., FCCP,&nbsp;Jennifer A. Szwak Pharm.D., FCCP,&nbsp;Lisa Hong Pharm.D.,&nbsp;Meredith L. Howard Pharm.D.","doi":"10.1002/jac5.1944","DOIUrl":"https://doi.org/10.1002/jac5.1944","url":null,"abstract":"<p>Research plays a vital role in advancing the pharmacy profession and improving patient care. It is a fundamental skill for learners to develop during their training under guided mentorship. Incorporating learners into research and quality improvement (QI) projects can yield numerous benefits for the learner, mentor, and institution. Despite this, there are barriers to integrating learners into research and QI projects which may stem from institutions and individuals. To ensure success when engaging in the research process, strategies centered around clear communication and illustrating the value should be implemented. Successful research programs require planning strategically, setting clear expectations, providing mentorship, and remaining adaptable to overcome barriers encountered during the process. The purpose of this paper is to discuss barriers to incorporating learners into research and QI projects and provide both mentors and learners strategies, tips and examples for success with perspectives and opinions from the American College of Clinical Pharmacy Adult Medicine and Education and Training Practice Research Networks.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 5","pages":"479-491"},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1944","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140895250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Insights into clinical pharmacy practice in Latin America” 就 "拉丁美洲临床药学实践的启示 "发表评论
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-18 DOI: 10.1002/jac5.1934
Gladys M. Delgado-Pérez Pharm.D., Ph.D., Cristopher E. Dávila-Espinoza Pharm.D., Guido A. Sardon-Beltran Pharm.D., Pool H. Flores Choque Pharm.D.
{"title":"Comment on “Insights into clinical pharmacy practice in Latin America”","authors":"Gladys M. Delgado-Pérez Pharm.D., Ph.D.,&nbsp;Cristopher E. Dávila-Espinoza Pharm.D.,&nbsp;Guido A. Sardon-Beltran Pharm.D.,&nbsp;Pool H. Flores Choque Pharm.D.","doi":"10.1002/jac5.1934","DOIUrl":"https://doi.org/10.1002/jac5.1934","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 3","pages":"279"},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to comment on “Insights into clinical pharmacy practice in Latin America” 对 "拉丁美洲临床药学实践的启示 "评论的答复
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-18 DOI: 10.1002/jac5.1935
Esteban Zavaleta-Monestel Pharm.D., Bruno Serrano-Arias Pharm.D., Antonella Milano-Gil Pharm.D., Cesar Sanchez-Solis Pharm.D., Dadier Antonio Arroyo-Monterrosa Pharm.D., Daniel Muñoz-Pichuante Pharm.D., Jorge Morales-Vallespin Pharm.D., Jose Pablo Diaz-Madriz Pharm.D., Mario Viñas-Veliz Pharm.D., Silvestre Dalmaso-Neto Pharm.D., Vania Teixeira-Ferreira Ph.D., Zoe Rojas-Barrantes Pharm. D., Jose Miguel Chaverri-Fernandez Pharm.D.
{"title":"Reply to comment on “Insights into clinical pharmacy practice in Latin America”","authors":"Esteban Zavaleta-Monestel Pharm.D.,&nbsp;Bruno Serrano-Arias Pharm.D.,&nbsp;Antonella Milano-Gil Pharm.D.,&nbsp;Cesar Sanchez-Solis Pharm.D.,&nbsp;Dadier Antonio Arroyo-Monterrosa Pharm.D.,&nbsp;Daniel Muñoz-Pichuante Pharm.D.,&nbsp;Jorge Morales-Vallespin Pharm.D.,&nbsp;Jose Pablo Diaz-Madriz Pharm.D.,&nbsp;Mario Viñas-Veliz Pharm.D.,&nbsp;Silvestre Dalmaso-Neto Pharm.D.,&nbsp;Vania Teixeira-Ferreira Ph.D.,&nbsp;Zoe Rojas-Barrantes Pharm. D.,&nbsp;Jose Miguel Chaverri-Fernandez Pharm.D.","doi":"10.1002/jac5.1935","DOIUrl":"https://doi.org/10.1002/jac5.1935","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 3","pages":"280-281"},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Part I: Case series: Acute management of prescription and nonprescription drug overdoses 第 I 部分:病例系列:处方药和非处方药过量的急性处理
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-18 DOI: 10.1002/jac5.1931
Ryan Feldman Pharm.D., James Leonard Pharm.D.
{"title":"Part I: Case series: Acute management of prescription and nonprescription drug overdoses","authors":"Ryan Feldman Pharm.D.,&nbsp;James Leonard Pharm.D.","doi":"10.1002/jac5.1931","DOIUrl":"https://doi.org/10.1002/jac5.1931","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 3","pages":"282-304"},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Part II: Case series: Acute agitation, delirium, and sleep management 第二部分:病例系列:急性躁动、谵妄和睡眠管理
Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-18 DOI: 10.1002/jac5.1932
Zachary R. Smith Pharm.D., FCCP
{"title":"Part II: Case series: Acute agitation, delirium, and sleep management","authors":"Zachary R. Smith Pharm.D., FCCP","doi":"10.1002/jac5.1932","DOIUrl":"https://doi.org/10.1002/jac5.1932","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 3","pages":"305-326"},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the American College of Clinical Pharmacy : JACCP
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1